Eagle Pharmaceuticals
50 Tice Blvd, Suite 315
Woodcliffe Lake
New Jersey
07677
United States
Tel: (201) 326-5300
Website: https://www.eagleus.com/
288 articles about Eagle Pharmaceuticals
-
Eagle Pharmaceuticals Provides Update on Bendamustine Intellectual Property Portfolio
1/18/2024
Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today provided an update on its bendamustine intellectual property portfolio.
-
Eagle Pharmaceuticals to Present Abstract on Post-hoc Analysis of Amisulpride at the 77th PGA (PostGraduate Assembly in Anesthesiology) in New York City
12/6/2023
Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that its abstract, a post-hoc analysis of two multicenter, placebo-controlled, Phase III studies evaluating amisulpride (a selective dopamine D2/D3 antagonist) as an antiemetic in patients with established postoperative nausea and vomiting, has been selected for a poster presentation at the 77th PGA (PostGraduate Assembly in Anesthesiology), being held December 8-11, 2023, in New York City.
-
Eagle Pharmaceuticals Announces Receipt of Notification of Deficiency from Nasdaq Regarding Requirement to Timely File Quarterly Report on Form 10-Q
11/29/2023
Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (the “Company”) today announced that it received a notice (the “Notice”) on November 27, 2023 from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) advising the Company that it is not currently in compliance with Nasdaq’s continued listing requirements.
-
Eagle Pharmaceuticals Announces Management Change
11/29/2023
Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced a change in management.
-
Eagle Delays Third Quarter 2023 Results and Conference Call
11/9/2023
Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that it will be delaying the release of its third quarter 2023 results and investor conference call, previously scheduled for today, Thursday, November 9, 2023.
-
Eagle Pharmaceuticals to Host Third Quarter 2023 Financial Results on November 9, 2023
11/8/2023
Eagle Pharmaceuticals, Inc. today announced that the Company will release its third quarter 2023 financial results on Thursday, November 9, 2023, before the market opens.
-
Eagle Pharmaceuticals Granted Patent for PEMFEXY®
10/24/2023
Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that the U.S. Patent and Trademark Office has granted the Company U.S. Patent No. 11,793,813 (“the ‘813 patent”) entitled “Pemetrexed Formulations.” Eagle has submitted the patent for listing in the U.S. Food and Drug Administration’s Orange Book.
-
Eagle Pharmaceuticals Granted Unique J-Code and Pass-Through Status for BARHEMSYS® from CMS
10/23/2023
Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that Centers for Medicare & Medicaid Services (“CMS”) has established a unique, product-specific billing code and granted transitional pass-through payment status for Barhemsys (amisulpride) injection.
-
Eagle Pharmaceuticals Awarded First Prize for Poster to Be Presented at the International Society for Anaesthetic Pharmacology 32nd Annual Meeting
10/4/2023
Eagle Pharmaceuticals, Inc. announced that its poster, to be presented at the International Society for Anaesthetic Pharmacology 32nd Annual Meeting, has been awarded first prize.
-
Eagle Pharmaceuticals to Present at the Cantor Global Healthcare Conference 2023
9/19/2023
Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that Scott Tarriff, Chief Executive Officer, and Brian Cahill, Chief Financial Officer, will participate in a panel presentation at the Cantor Global Healthcare Conference 2023.
-
Eagle Pharmaceuticals to Present CAL02 Trial in Progress at the 2023 ASM/ESCMID Joint Conference on Drug Development to Meet the Challenge of Antimicrobial Resistance
9/11/2023
Eagle Pharmaceuticals, Inc. has been selected for a poster presentation at the conference co-sponsored by the American Society for Microbiology (“ASM”) and the European Society for Clinical Microbiology and Infectious Diseases (“ESCMID”).
-
Eagle Pharmaceuticals to Present BYFAVO® (remimazolam) for Injection Abstract at Prestigious Society for Neuroscience in Anesthesiology and Critical Care (SNACC) Conference
8/30/2023
Eagle Pharmaceuticals, Inc. announced that it has been selected to present a platform presentation at the Society for Neuroscience in Anesthesiology and Critical Care Annual Meeting being held September 8-10, 2023, in Alexandria, VA.
-
Eagle Pharmaceuticals Announces Positive Type C Meeting with FDA for EA-114, an Estrogen Receptor Antagonist Used in the Treatment of Metastatic Breast Cancer in Post-Menopausal Women
8/29/2023
Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced a positive Type C meeting with the U.S. Food and Drug Administration (“FDA”). Eagle and the FDA agreed on a path forward to advance the clinical development of EA-114, an estrogen receptor antagonist used in the treatment of breast cancer in post-menopausal women.
-
Eagle Pharmaceuticals to Present at Two Upcoming September 2023 Healthcare Conferences
8/22/2023
Eagle Pharmaceuticals, Inc. announced that Scott Tarriff, Chief Executive Officer, and Brian Cahill, Chief Financial Officer, will present at the following healthcare conferences:.
-
Eagle Pharmaceuticals Reiterates 2023 Adjusted non-GAAP EBITDA and Adjusted non-GAAP E¹ Guidance
8/17/2023
Eagle Pharmaceuticals, Inc. reiterated its previously issued guidance for the 2023 fiscal year.
-
Eagle Pharmaceuticals Reports Second Quarter 2023 Results
8/8/2023
Eagle Pharmaceuticals, Inc. announced financial results for the three and six months ended June 30, 2023.
-
Eagle Pharmaceuticals to Host Second Quarter 2023 Financial Results on August 8, 2023
8/1/2023
Eagle Pharmaceuticals, Inc. announced that the Company will release its second quarter 2023 financial results on Tuesday, August 8, 2023, before the market opens.
-
Eagle Pharmaceuticals Raises 2023 Adjusted non-GAAP EPS¹ Guidance
7/31/2023
Eagle Pharmaceuticals, Inc. announced that it has raised its Adjusted non-GAAP earnings per share and Adjusted non-GAAP EBITDA guidance for the 2023 fiscal year.
-
Eagle Pharmaceuticals Announces First Patient Randomized in Phase 2 Study Evaluating CAL02, a Novel First-in-Class Anti-Toxin Drug Candidate, in Severe Community-Acquired Bacterial Pneumonia (SCABP)
7/24/2023
Eagle Pharmaceuticals, Inc. announced that the first patient has been randomized in its multi-center adaptive, randomized, double-blind, placebo-controlled Phase 2 study designed to assess the efficacy and safety of CAL02 administered intravenously in addition to standard of care in patients with severe community-acquired bacterial pneumonia.
-
Eagle Pharmaceuticals Provides Business Update and Reiterates 2023 Guidance
6/15/2023
Eagle Pharmaceuticals, Inc. provided a business update and reiterated its 2023 financial guidance.